Hyperbaric Chamber for Diabetes: Wound Healing, Research & What to Know

hyperbaric oxygen therapy for diabetes has one of the strongest evidence bases in all of hyperbaric medicine, particularly for diabetic foot ulcers. It is one of only 14 FDA-cleared indications for HBOT, and it is routinely covered by insurance. Beyond wound healing, emerging research suggests HBOT may also benefit diabetic neuropathy and certain metabolic markers, though these applications are still under investigation. If you’re considering this route, our treatment costs is worth reading. It is one of several HBOT for chronic conditions that researchers are actively investigating.

Diabetes affects more than 37 million Americans, and its complications range from slow-healing wounds to nerve damage and vascular disease. Hyperbaric oxygen therapy works by flooding the body with 100% oxygen at elevated pressure, which can jumpstart healing processes that diabetes has impaired. For diabetic wounds specifically, this is not experimental or fringe. It is a well-established medical treatment backed by decades of clinical evidence.

FDA-Approved: HBOT for Diabetic Foot Ulcers

FDA-cleared for diabetic foot ulcers, HBOT has been shown to reduce amputation risk by 26% and accelerate wound healing in patients with severe (Wagner grade 3+) ulcers that fail to respond to 30 days of standard treatment.²

Diabetic foot ulcers are one of the most serious complications of diabetes. Roughly 15% of people with diabetes will develop a foot ulcer during their lifetime¹, and these wounds are the leading cause of non-traumatic lower-limb amputations in the United States. Standard wound care resolves many of these ulcers, but a significant percentage become chronic and resistant to healing. We cover this topic thoroughly in our UHMS approved indications including diabetic wounds. This is where HBOT has its strongest evidence. The FDA has cleared hyperbaric oxygen therapy as an adjunctive treatment for chronic, non-healing diabetic wounds. During treatment, patients breathe 100% oxygen at pressures of 2.0 to 2.4 atmospheres absolute (ATA), which dramatically increases the amount of dissolved oxygen in the blood and tissues.

How Does HBOT Work at the Cellular Level?

Diabetes impairs wound healing through several mechanisms: poor blood flow, reduced oxygen delivery to tissues, impaired immune response, and diminished growth factor production. HBOT addresses these problems directly:

• Oxygen delivery: Hyperbaric conditions can increase tissue oxygen levels by 10 to 15 times normal, reaching even areas with compromised blood supply.
• Angiogenesis: Repeated HBOT sessions stimulate the growth of new blood vessels in oxygen-depleted tissue, restoring circulation to the wound bed.
• Collagen synthesis: Oxygen is required for collagen production, the structural protein essential for wound closure. HBOT provides the oxygen that diabetic tissues lack.
• Infection control: Elevated oxygen levels enhance white blood cell function and are directly toxic to certain anaerobic bacteria commonly found in diabetic wounds.

What Does the Research Say?

A Cochrane systematic review found that HBOT significantly improved ulcer healing at six weeks compared to standard care alone. A large multicenter randomized controlled trial published in Diabetes Care demonstrated that HBOT reduced the risk of major amputation and improved complete healing rates in patients with chronic diabetic foot ulcers. Multiple studies have shown healing rates of 70% to 90% when HBOT is added to comprehensive wound care, compared to 20% to 50% with wound care alone in refractory cases. Curious about this? Our Cochrane review on HBOT for chronic diabetic foot ulcers has the full picture.

The evidence is strong enough that both the Undersea and Hyperbaric Medical Society (UHMS) and the Wound Healing Society include HBOT in their clinical practice guidelines for diabetic lower-extremity wounds. For a deeper look at the wound healing evidence, see our full guide on hyperbaric chamber for wound healing.

In a 2025 systematic review of 6 studies with 391 patients, HBOT significantly improved diabetic ulcer size and depth reduction in 4 of 6 studies, with treated patients healing faster and remaining healed at 1-year follow-up.³

Diabetic Neuropathy

Diabetic neuropathy affects up to 50% of people with diabetes and causes numbness, tingling, burning pain, and loss of sensation, most commonly in the feet and legs. It is driven by chronic nerve damage from high blood sugar, poor microcirculation, and oxidative stress. Research on HBOT for diabetic neuropathy is still in the early stages, but the results so far are encouraging. Several clinical studies have reported meaningful improvements in neuropathic symptoms after a course of hyperbaric treatments.

The Mechanism

HBOT may benefit neuropathy through two primary pathways:

• Improved nerve oxygenation: Peripheral nerves in diabetic patients are often oxygen-starved due to microvascular disease. HBOT delivers oxygen directly to these tissues at concentrations that passive circulation cannot achieve.
• Microcirculation restoration: By stimulating angiogenesis in the small blood vessels that feed peripheral nerves, HBOT may help restore the nutrient supply that nerves need to function and repair.

A 2021 study in the Journal of Diabetes Research found that patients who received 30 sessions of HBOT showed significant improvements in nerve conduction velocity and reported reduced pain scores compared to a control group. Other studies have shown improvements in tactile sensation and vibration perception thresholds after treatment.

HBOT is not FDA-cleared specifically for neuropathy, and the studies to date are relatively small. Larger randomized controlled trials are needed before neuropathy becomes a standard indication. If neuropathy is your primary concern, read our dedicated guide on hyperbaric chamber for neuropathy for a complete overview of the current evidence.

Broader Metabolic Effects

A smaller body of research has explored whether HBOT might influence the metabolic dysfunction at the core of diabetes, including blood sugar regulation and insulin sensitivity. This evidence is preliminary, and it is important to set expectations accordingly. Some animal studies and small human trials have reported temporary improvements in fasting blood glucose and insulin sensitivity following HBOT. The proposed mechanism involves improved mitochondrial function and reduced inflammation, both of which play roles in insulin resistance. A few studies have also noted reductions in HbA1c levels after extended HBOT courses.

That said, these findings are not consistent across studies, and no clinical guidelines recommend HBOT as a treatment for glycemic control. The metabolic effects, if real, appear to be modest and may not persist after treatment ends. Anyone considering HBOT for blood sugar management should understand that this is an active area of research, not an established application.

For a broader look at what the science says across all indications, visit our HBOT research overview.

Treatment Protocols

HBOT protocols for diabetes-related conditions follow well-established clinical guidelines, particularly for wound healing.

Diabetic Foot Ulcers (Standard Protocol)

• Pressure: 2.0 to 2.4 ATA (most commonly 2.0 ATA)
• Session length: 90 minutes of oxygen breathing time per session
• Frequency: Once daily, five days per week
• Total sessions: 30 to 40 sessions (6 to 8 weeks), with reassessment after 20 sessions
• Setting: Hospital-based or outpatient wound care center with a medical-grade monoplace or multiplace chamber

Some protocols include a reassessment at 20 sessions to evaluate progress. If the wound shows measurable improvement (such as a reduction in wound size or depth), treatment continues. If no improvement is observed, the care team may reconsider the approach.

Neuropathy (Investigational Protocol)

There is no standardized protocol for diabetic neuropathy, but research studies have typically used 20 to 30 sessions at 2.0 to 2.4 ATA. These sessions follow a similar daily schedule as wound care protocols.

For a complete breakdown of how sessions work, what to expect during HBOT, and how to prepare, see our HBOT sessions guide.

How Much Does HBOT Cost?

This is one of the few areas in hyperbaric medicine where insurance works in your favor. Because diabetic wound healing is an FDA-cleared indication, most insurance plans cover HBOT when specific criteria are met:

• The wound must be a Wagner grade III or higher diabetic foot ulcer (or meet equivalent severity criteria).
• The wound must have failed to respond to at least 30 days of standard wound care.
• The patient must be receiving concurrent comprehensive wound management.
• Treatment must be provided in an accredited facility.

Medicare covers HBOT for diabetic wounds under these conditions, and most commercial insurers follow similar guidelines. Patients can typically expect coverage for up to 40 sessions, though prior authorization is almost always required.

For neuropathy and metabolic indications, HBOT insurance coverage is unlikely since these are not FDA-cleared uses. Patients pursuing HBOT for neuropathy would typically pay out of pocket. Our insurance coverage guide explains exactly how to navigate prior authorization and appeal denials.

What Does the HBOT Protocol Look Like?

Wound Healing Timeline

Results vary depending on wound severity, blood sugar control, and overall health, but here is a general timeline based on clinical data:

• Sessions 1 to 10: Reduced wound drainage and inflammation. The wound bed may begin to look healthier with more granulation tissue.
• Sessions 10 to 20: Measurable reduction in wound size. New blood vessel formation becomes evident. Pain levels often decrease.
• Sessions 20 to 40: Progressive wound closure. Many patients achieve full or near-full closure by the end of treatment.

A study in Diabetes Care found that 52% of HBOT-treated wounds achieved complete healing within one year, compared to 29% in the control group. For complex or large wounds, some patients may need additional sessions beyond 40.

Neuropathy Symptom Improvement

Patients in neuropathy studies have reported noticeable reductions in burning pain and tingling within the first 10 to 15 sessions. Improvements in sensation and nerve conduction velocity tend to become measurable by session 20 to 30. The durability of these improvements is still being studied, and some patients may benefit from periodic maintenance sessions.

Who Should Not Try HBOT

HBOT is generally safe when administered by trained professionals, but it is not appropriate for everyone. Discuss your full medical history with your provider before starting treatment.

Absolute Contraindications

HBOT should not be used if you have:

• Untreated pneumothorax (collapsed lung) – pressure changes can worsen this condition and become life-threatening
• Certain chemotherapy drugs – bleomycin, cisplatin, doxorubicin, and disulfiram may interact dangerously with high-oxygen environments

Relative Contraindications

Your provider may need to take extra precautions or postpone treatment if you have:

• Upper respiratory infection or sinus congestion – difficulty equalizing pressure can cause ear or sinus barotrauma
• Seizure disorder – high-pressure oxygen can lower seizure threshold in susceptible individuals
• Chronic obstructive pulmonary disease (COPD) – altered breathing drive may require modified protocols
• High fever – increases the risk of oxygen toxicity
• History of ear surgery or chronic ear problems – pressure equalization may be difficult or risky
• Claustrophobia – may require sedation or use of a multiplace chamber instead
• Pregnancy – insufficient safety data exists for routine use during pregnancy

Talk to Your Doctor First

Even if you do not have the conditions listed above, always consult your physician before starting HBOT, especially if you take insulin (blood sugar may drop during treatment), have a pacemaker or implanted device, or are currently taking any medications. For a full overview of HBOT side effects and risks, see our detailed guide.

References

1. StatPearls. “Hyperbaric Treatment of Diabetic Foot Ulcers.” NCBI NBK430783. NBK430783
2. Santema KTB, et al. Cited in: 2025 Systematic Review PMC11890413. 26% absolute risk reduction in amputation with HBOT vs. standard care.
3. 2025 Systematic Review. “Clinical Outcomes of Hyperbaric Oxygen Therapy for Diabetic Foot Ulcers.” PMC11890413. PMC11890413
4. Weng J, et al. “Meta-analysis of HBOT for diabetic peripheral neuropathy.” Medicine. 2024. DOI: 10.1097/MD.0000000000039699